Bladder Pain Syndrome Treated with Triple Therapy with Gabapentin, Amitriptyline, and a Nonsteroidal Anti-Inflammatory Drug.
- Author:
Jea Whan LEE
1
;
Dong Youp HAN
;
Hee Jong JEONG
Author Information
1. Department of Urology and The Institute of Wonkwang Medical Sciences, Wonkwang University School of Medicine, Iksan, Korea. uro94c@wonkwang.ac.kr
- Publication Type:Original Article
- Keywords:
Bladder pain syndrome;
Interstitial cystitis;
Visual analog scale
- MeSH:
Amines;
Amitriptyline;
Chronic Disease;
Cyclohexanecarboxylic Acids;
Cystitis, Interstitial;
Female;
Follow-Up Studies;
gamma-Aminobutyric Acid;
Humans;
Male;
Nocturia;
Prospective Studies;
Urinary Bladder;
Weights and Measures
- From:International Neurourology Journal
2010;14(4):256-260
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Bladder pain syndrome is a chronic disease that manifests as bladder pain, frequency, nocturia, and urgency. Gabapentin, amitriptyline, and nonsteroidal anti-inflammatory drugs are efficacious treatments for bladder pain syndrome. Here, we assessed the effect of triple therapy with these drugs in women with bladder pain syndrome. METHODS: Between May 2007 and May 2010, we conducted a prospective nonrandomized study on 74 patients with bladder pain syndrome. Of these patients, 38 (11 men and 27 women; mean age, 55.9 years; range, 25 to 77 years; mean follow-up, 12.6 months) were administered the interstitial cystitis (IC) symptom scales (O'Leary-Sant Symptom Index) and visual analog scale (VAS) 1, 3, and 6 months after treatment to assess the efficacy of triple therapy. RESULTS: The pretreatment O'Leary-Sant IC symptom score was 11.7, and the post-treatment scores were 4.4, 3.8, and 4.0 at 1, 3, and 6 months, respectively; the pretreatment problem index score was 10.5, and the post-treatment scores were 3.7, 2.7, and 2.9 at 1, 3, and 6 months, respectively. The pretreatment VAS score was 6.7, and the post-treatment scores were 1.8, 1.5, and 1.7 at 1, 3, and 6 months, respectively. The O'Leary-Sant IC symptom index and problem index and VAS scores improved considerably 1 month after treatment (P<0.05). However, the results at 1, 3, and 6 months after treatment were not significantly different (P>0.05). CONCLUSIONS: Triple therapy was sufficiently effective in patients with bladder pain syndrome and caused no significant adverse effects. However, large-scale studies should be performed to verify our findings.
